Evolocumab improves myocardial remodelling and cardiac function in metabolic syndrome models by suppressing PCSK9-mediated activation of the NLRP3 inflammasome and its downstream Caspase-1/IL-1β axis [150]. The gene discussed is PCSK9; the disease is metabolic syndrome.